DIAMEDICA THERAPEUTICS INC
DMACNASDAQTrading Snapshot
- Day Range
- $8.60 – $10.13
- 52-Week Range
- $5.25 – $10.42
- Volume (shares)
- 519,652
- Avg Volume (shares)
- —
- Shares Outstanding
- 53.9M
- Next Earnings
- 2026-11-18
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- -12.1
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.70
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +9.7%
DIAMEDICA THERAPEUTICS INC
DMAC
StockOtter · stockotter.spaceAbout DIAMEDICA THERAPEUTICS INC
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth res
DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction (FGR) and acute ische
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic st
DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth res
Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 130% in DiaMedica Therapeutics (DMAC). While the effectiveness of this highly sought-after metric is questionable, the positive tre
All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy
DiaMedica Therapeutics (DMAC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).